Vaxcyte, Inc.
NASDAQ:PCVXBiotechnology
+$1.94 today
- Market cap
- $9.26B
- Beta
- 1.24
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$6.78
Volume 1.13M
Average 1.44M
PCVX Sales of Investments
Cash received from selling or redeeming investments.
Vaxcyte, Inc.NASDAQ: PCVX
Sales of Investments · Q2 FY2026 · quarter ended Jun 2026
Sales of investments growth accelerates
Q2 FY2026 sales of investments of $786.48M rose 80.2% year over year, ahead of the +26.8% change in trailing-twelve-month sales of investments. Sequentially, it rose 115.2% from the prior quarter. Over 3 fiscal years it compounded at +110.4% a year.
Context
- Sales of investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +80.2% holds above the trailing-twelve-month pace of +26.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 1.71B USD
- Year-over-year change
- +42.1%
- 4-year CAGR
- +90.1%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.71B | +42.1% |
| FY2024 | 2024-12-31 | 1.2B | +92.2% |
| FY2023 | 2023-12-31 | 624.46M | +240.9% |
| FY2022 | 2022-12-31 | 183.17M | +40.3% |
| FY2021 | 2021-12-31 | 130.56M | — |
Sales of Investments vs competitors
How PCVX compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +26.8% is the 2nd highest of 6, against a peer median of -26.1%.
- Over three fiscal years its annual growth of +110.4% compares with a peer median of -3.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $12.53B USD | -38.1% | -20.7% | 19.7% | |
| LTM Sep 2026 | $5.45B USD | -34.0% | +5.7% | 215.6% | |
| LTM Jun 2026 | $1.96B USD | +26.8% | +110.4% | — | |
| LTM Mar 2026 | $1.07B USD | -26.1% | +50.6% | 1633.7% | |
| LTM Mar 2026 | $458.02M USD | -5.9% | — | 76.8% | |
| LTM Jun 2026 | £385.84M GBP | — | -12.7% | 1.2% | |
| LTM Sep 2026 | $374.39M USD | +1501.0% | — | 205.1% | |
| LTM Mar 2026 | €1.39M EUR | — | — | 0.9% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding PCVX) | — | -26.1% | -3.5% | 48.2% | |
Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (100.08M) | (223.49M) | (402.27M) | (463.93M) | (766.63M) |
| Depreciation & Amortization | 3.46M | 9.45M | 10.17M | 15.85M | 24.86M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.73M | 23.65M | 48.76M | 84.82M | 138.85M |
| Change in Working Capital | (37.01M) | 12.74M | 81.32M | (54.9M) | (3.45M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (12.47M) | 2.9M | 11.23M | 34.58M | 19.91M |
| Other Working Capital | (24.54M) | 9.84M | 70.1M | (89.48M) | (23.36M) |
| Other Non-Cash Items | 1.5M | 7.05M | (34.78M) | (34.47M) | (49.2M) |
| Operating Cash Flow | (121.39M) | (170.6M) | (296.79M) | (452.63M) | (655.58M) |
| Capital Expenditures | (6.56M) | (5.84M) | (67.88M) | (22.43M) | (13.71M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (336.34M) | (102.75M) | (1.33B) | (3.09B) | (1.21B) |
| Sales of Investments | 130.56M | 183.17M | 624.46M | 1.2B | 1.71B |
| Other Investing Activities | 26K | 0 | 0 | (96.73M) | (43.26M) |
| Investing Cash Flow | (212.31M) | 74.59M | (773.31M) | (2.01B) | 437.35M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 13.9M | 856.48M | 636.04M | 2.44B | 13.01M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.9M | 5.07M | 3.77M | 12.85M | (10.99M) |
| Financing Cash Flow | 17.8M | 861.55M | 639.81M | 2.45B | 2.01M |
| Effect of Forex Changes | (439K) | 137K | (6.69M) | 426K | 2.44M |
| Net Change in Cash | (316.34M) | 765.67M | (436.97M) | (9.36M) | (213.77M) |
| Free Cash Flow | (127.95M) | (176.44M) | (364.67M) | (475.05M) | (669.29M) |
Vaxcyte, Inc.
NASDAQ:PCVX
Intrinsic Alpha fair value
Locked
Current Price
$58.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.